124 related articles for article (PubMed ID: 38013240)
1. Safety and efficacy of SARS-CoV-2 vaccination in patients with immune thrombocytopenia: A two-centre review.
Stefani S; Buti N; Hart ACJ; Paul D; Rizvi N; Ragoonanan V; Vladescu C; Szydlo R; Ademokun C; Jansen AJG; Cooper N
Br J Haematol; 2024 Jan; 204(1):324-328. PubMed ID: 38013240
[TBL] [Abstract][Full Text] [Related]
2. Real-world, single-center experience of SARS-CoV-2 vaccination in immune thrombocytopenia.
Woolley P; Tailor A; Shah R; Westwood JP; Scully M
J Thromb Haemost; 2022 Jun; 20(6):1476-1484. PubMed ID: 35313390
[TBL] [Abstract][Full Text] [Related]
3. Treatment, outcome and re-vaccination of patients with SARS-CoV-2 vaccine-associated immune thrombocytopenia.
Ruzicka M; Wurm S; Lindner L; Dreyling M; von Bergwelt-Baildon M; Boeck S; Giessen-Jung C; Milani V; Stemmler JH; Subklewe M; Weigert O; Spiekermann K
Infection; 2023 Feb; 51(1):231-238. PubMed ID: 36195695
[TBL] [Abstract][Full Text] [Related]
4. Humoral response to mRNA-based COVID-19 vaccine in patients with immune thrombocytopenia.
Mori A; Onozawa M; Kobayashi M; Tsukamoto S; Senjo H; Ishio T; Yokoyama E; Izumiyama K; Saito M; Muraki H; Morioka M; Teshima T; Kondo T
Br J Haematol; 2023 Mar; 200(6):717-721. PubMed ID: 36442510
[TBL] [Abstract][Full Text] [Related]
5. Effects of COVID-19 vaccination on platelet counts and bleeding in children, adolescents, and young adults with immune thrombocytopenia.
Kaicker S; Martinko K; Bussel JB
Pediatr Blood Cancer; 2023 Jan; 70(1):e30051. PubMed ID: 36317671
[TBL] [Abstract][Full Text] [Related]
6. Autoimmune haemolytic anaemia and immune thrombocytopenia following SARS-CoV-2 and non-SARS-CoV-2 vaccination: 32 Years of passive surveillance data.
Jacobs JW; Booth GS; Guarente J; Schlafer D; Zheng L; Adkins BD
Br J Haematol; 2023 Apr; 201(2):227-233. PubMed ID: 36564040
[TBL] [Abstract][Full Text] [Related]
7. Clinical characteristics in immune thrombocytopenia patients after COVID-19 vaccination.
Feng Y; Quan Y; Cassady K; Zou Z; Gao Y; Zhang X
Hum Vaccin Immunother; 2022 Nov; 18(6):2119043. PubMed ID: 36069667
[TBL] [Abstract][Full Text] [Related]
8. A Case Report of Immune Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination.
Kim G; Choi EJ; Park HS; Lee JH; Lee JH; Lee KH
J Korean Med Sci; 2021 Nov; 36(43):e306. PubMed ID: 34751013
[TBL] [Abstract][Full Text] [Related]
9. Immune thrombocytopenic purpura secondary to COVID-19 vaccination: A systematic review.
Bidari A; Asgarian S; Pour Mohammad A; Naderi D; Anaraki SR; Gholizadeh Mesgarha M; Naderkhani M
Eur J Haematol; 2023 Apr; 110(4):335-353. PubMed ID: 36562217
[TBL] [Abstract][Full Text] [Related]
10. Immune thrombocytopenia following immunisation with Vaxzevria ChadOx1-S (AstraZeneca) vaccine, Victoria, Australia.
Gordon SF; Clothier HJ; Morgan H; Buttery JP; Phuong LK; Monagle P; Chunilal S; Wood EM; Tran H; Szer J; Crawford NW;
Vaccine; 2021 Nov; 39(48):7052-7057. PubMed ID: 34756770
[TBL] [Abstract][Full Text] [Related]
11. [Immune thrombocytopenia after BNT162b2 mRNA COVID-19 vaccination].
Sato K; Anayama M; Sumi M; Kobayashi H
Rinsho Ketsueki; 2021; 62(12):1688-1693. PubMed ID: 35022338
[TBL] [Abstract][Full Text] [Related]
12. Analysis of hematologic adverse events reported to a national surveillance system following COVID-19 bivalent booster vaccination.
Jacobs JW; Booth GS; Adkins BD
Ann Hematol; 2023 Apr; 102(4):955-959. PubMed ID: 36795118
[TBL] [Abstract][Full Text] [Related]
13. SARS-CoV-2 vaccination and ITP in patients with de novo or preexisting ITP.
Lee EJ; Beltrami-Moreira M; Al-Samkari H; Cuker A; DiRaimo J; Gernsheimer T; Kruse A; Kessler C; Kruse C; Leavitt AD; Lee AI; Liebman HA; Newland AC; Ray AE; Tarantino MD; Thachil J; Kuter DJ; Cines DB; Bussel JB
Blood; 2022 Mar; 139(10):1564-1574. PubMed ID: 34587251
[TBL] [Abstract][Full Text] [Related]
14. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
Akova M; Unal S
Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
[TBL] [Abstract][Full Text] [Related]
15. Successful mRNA SARS-Cov-2 vaccine rechallenge after a first episode of immune thrombocytopenic purpura.
Chanut M; Jaidi R; Kohn M; Grange T; Brones C; Lombion N; Rousselot P; Longval T
Platelets; 2022 May; 33(4):652-653. PubMed ID: 35225144
[TBL] [Abstract][Full Text] [Related]
16. Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial.
Chen GL; Li XF; Dai XH; Li N; Cheng ML; Huang Z; Shen J; Ge YH; Shen ZW; Deng YQ; Yang SY; Zhao H; Zhang NN; Zhang YF; Wei L; Wu KQ; Zhu MF; Peng CG; Jiang Q; Cao SC; Li YH; Zhao DH; Wu XH; Ni L; Shen HH; Dong C; Ying B; Sheng GP; Qin CF; Gao HN; Li LJ
Lancet Microbe; 2022 Mar; 3(3):e193-e202. PubMed ID: 35098177
[TBL] [Abstract][Full Text] [Related]
17. Thrombotic thrombocytopenic purpura (TTP) after COVID-19 vaccination: A systematic review of reported cases.
Saluja P; Gautam N; Yadala S; Venkata AN
Thromb Res; 2022 Jun; 214():115-121. PubMed ID: 35533526
[TBL] [Abstract][Full Text] [Related]
18. Antibody levels following vaccination against SARS-CoV-2: associations with post-vaccination infection and risk factors in two UK longitudinal studies.
Cheetham NJ; Kibble M; Wong A; Silverwood RJ; Knuppel A; Williams DM; Hamilton OKL; Lee PH; Bridger Staatz C; Di Gessa G; Zhu J; Katikireddi SV; Ploubidis GB; Thompson EJ; Bowyer RCE; Zhang X; Abbasian G; Garcia MP; Hart D; Seow J; Graham C; Kouphou N; Acors S; Malim MH; Mitchell RE; Northstone K; Major-Smith D; Matthews S; Breeze T; Crawford M; Molloy L; Kwong ASF; Doores K; Chaturvedi N; Duncan EL; Timpson NJ; Steves CJ
Elife; 2023 Jan; 12():. PubMed ID: 36692910
[TBL] [Abstract][Full Text] [Related]
19. Successful Treatment of Immune Thrombocytopenic Purpura with Intracranial Hemorrhaging and Duodenal Bleeding Following SARS-CoV-2 Vaccination.
Baba Y; Sakai H; Kabasawa N; Harada H
Intern Med; 2022 Jun; 61(12):1891-1895. PubMed ID: 35400701
[TBL] [Abstract][Full Text] [Related]
20. Safety and immunogenicity of a protein subunit COVID-19 vaccine (ZF2001) in healthy children and adolescents aged 3-17 years in China: a randomised, double-blind, placebo-controlled, phase 1 trial and an open-label, non-randomised, non-inferiority, phase 2 trial.
Gao L; Li Y; He P; Chen Z; Yang H; Li F; Zhang S; Wang D; Wang G; Yang S; Gong L; Ding F; Ling M; Wang X; Ci L; Dai L; Gao GF; Huang T; Hu Z; Ying Z; Sun J; Zuo X
Lancet Child Adolesc Health; 2023 Apr; 7(4):269-279. PubMed ID: 36803632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
